What is PRLD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.31B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PRLD?

P/E (TTM) is n/a and 52-week range is $1.15 to $6.83 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PRLD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PRLD?

The company profile lists revenue (TTM) near $18M, net income (TTM) near $-4.90B, EPS (TTM) near $-0.73 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Prelude Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wilmington, Delaware, US, 79.7M shares outstanding, ISIN US74065P1012 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Prelude Therapeutics Inc

$PRLD

Health Care · Biotechnology

IR Run Scenarios

$3.89

+0.26%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 79 full-time employees. The company went IPO on 2020-09-25. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The firm has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.

Employees

Website

preludetx.com/

IPO

2020-09-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)